Will Only the Wealthy Live Longer? The Ethics and Economics of Longevity Inequality
As longevity and preventive care treatments gain popularity at expensive clinics, concerns about unequal access to life-extending technologies are growing. With annual therapy costs reaching six figures and no insurance coverage, extended lifespan is increasingly a privilege for the wealthy.
Research published in JAMA Internal Medicine revealed that the richest 1% of American men live 15 years longer than the poorest 1%. For women, that gap is 10 years. Between 2001 and 2014, life expectancy for the top 5% of earners increased by more than 2 years, while the bottom 5% gained almost nothing (Chetty et al., 2016).
The growing longevity industry in the United States is launching private clinics and new treatments to slow biological aging, such as biomarker testing, metabolic optimization, peptide therapies, and cellular diagnostics. These expensive advances are out of reach for most people, many of whom already struggle to afford standard health insurance. As a result, advanced care remains accessible mainly to the wealthy, increasing inequality.
The longevity healthcare market mirrors economic class divisions. Top-tier clinics in the U.S., Switzerland, Singapore, and the Gulf charge annual memberships from $10,000 to $50,000, with executive packages exceeding $100,000 (Demaria, 2025). Most do not accept health insurance. Recently, NextHealth, a franchise-based clinic, has begun offering relatively lower-cost treatments (NextHealth Franchising, 2024).
If access to advanced longevity treatments remains limited, the gap may widen, creating a multi-tiered society. The wealthy would benefit from new therapies, while lower-income groups would be unable to afford these treatments and miss out on longer, healthier lives. Most longevity clinics and biotech innovation are concentrated in major metropolitan and suburban areas, further restricting access for rural and low-income communities.
Unequal access to longevity technologies will likely have negative economic effects, limiting seniors' earnings and making retirement more challenging. Wealthier individuals may work and earn longer, while disadvantaged groups face shorter lives and fewer opportunities to build income and savings (World Economic Forum, 2024). This generational divide may continue to widen over time.
Even relatively affordable therapies require policy attention from governments and nonprofits. Metformin and rapamycin cost $13.72 and $100 per month, but neither is approved for longevity (Pryde & Blasco, 2017), which denies low-income individuals the chance to extend their health and lifespan. Higher-income individuals can use off-label prescribing, further widening healthcare inequalities.
Governments could regulate longevity treatment pricing, expand public health insurance to cover approved therapies, and invest more in preventive care research to improve access. Policymakers in developed countries, especially in Europe, are considering several specific actions, including:
Expand Medicare and Medicaid coverage to include evidence-based longevity interventions, starting with coverage for proven generics such as metformin.
Require biotech recipients of federal R&D funding in longevity to conduct research that delivers direct public health benefits (American Medical Association [AMA], 2025).
Reform Social Security's retirement ages with provisions that account for longevity inequality to prevent those with shorter lifespans from bearing disproportionate benefit reductions.
Support the classification of aging as a "treatable condition" by regulatory bodies such as the FDA, and ensure longevity treatments are covered by insurance or national health services to encourage mass production and lower costs (National Institute on Aging [NIA], 2024; Womble Bond Dickinson, 2024).
Will the wealth gap grow as longevity gaps widen? Could society become segregated by lifespan in the future?
References
American Medical Association [AMA]. (2025). Should clinicians be agents of anti-aging? AMA Journal of Ethics, 27(12), 859-865. https://journalofethics.ama-assn.org/article/should-clinicians-be-agents-anti-aging/2025-12
Chetty, R., Stepner, M., Abraham, S., Lin, S., Scuderi, B., Turner, N., Bergeron, A., & Cutler, D. (2016). The association between income and life expectancy in the United States, 2001-2014. JAMA, 315(16), 1750–1766. https://doi.org/10.1001/jama.2016.4226
Demaria, M. (2025). Longevity clinics: between promise and peril. Aging, 17(10), 2452–2454. https://doi.org/10.18632/aging.205831
National Institute on Aging [NIA]. (2024). Information on FDA review of geroscience-related IND applications. National Institutes of Health. https://www.nia.nih.gov/research/information-fda-review-geroscience-related-ind-applications
Next Health Franchising LLC. (2024). Franchise Disclosure Document: NextHealth Center Operations. State of Delaware Department of Corporations. (Note: Public legal registry document accessed via official state corporate filing archives).
Pryde, K. R., & Blasco, M. A. (2017). Towards natural mimetics of metformin and rapamycin. Aging-US, 9(11), 2245-2268. https://doi.org/10.18632/aging.101319
Womble Bond Dickinson. (2024). FDA and the fountain of youth: Regulatory hurdles in the longevity biotech community. WBD Legal Insights. https://www.womblebonddickinson.com/us/insights/blogs/fda-and-fountain-youth-regulatory-hurdles-longevity-biotech-community
World Economic Forum. (2024). The global risks report 2024 (19th ed.). World Economic Forum Publications. https://www.weforum.org/publications/global-risks-report-2024/
